Jin, J. X., Ginde, V. R., Huhn, S., Reichert, P., Bertsch, U., Fenk, R., Besemer, B., Boquoi, A., Schroers, R., Metzler, I. V., Hänel, M., Mann, C., Leypoldt, L. B., Heilmeier, B., Scheid, C., Peters-Regehr, T., Blau, I. W., Müller-Tidow, C., Luntz, S., Holderried, T. A., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Shumilov, E., Knauf, W., Michel, C. S., Geer, T., Riesenberg, H., Lutz, C., Raab, M. S., Weinhold, N., Hoffmann, M., Benner, A., Findeisen, P., Weisel, K. C., Salwender, H. J., Mai, E. K., Goldschmidt, H. (2026). Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01346